- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01630252
PGL5001 Proof of Concept Study in Inflammatory Endometriosis (JADE)
A Phase IIa Efficacy and Safety Study of PGL5001 Versus Placebo Administered for up to 5 Months With Concomitant Administration of Depot Medroxyprogesterone Acetate for the Treatment of Peritoneal and/or Ovarian Endometriosis With an Inflammatory Component.
This is a prospective, three-part (Part A1, Part A2 and Part B),Phase II study investigating the efficacy, safety, pharmacokinetics and pharmacodynamics of the JNK inhibitor PGL5001 orally administered for up to 5 months with concomitant DMPA administration for the treatment of laparoscopically diagnosed inflammatory endometriosis. The part A1 is open-label, the parts A2 and B are double-blind.
The target population will be women of reproductive age and suffering from newly diagnosed peritoneal and/or ovarian endometriosis.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Bialystok, Polen, 15-224
- Prywatna Klinika Połozniczo-Ginekologiczna Sp z o.o.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- The Subject must provide written informed consent prior to initiation of any study related procedures.
- The Subject must be an adult woman of reproductive age, aged from 18 and above.
- The Subject must be a newly diagnosed patient suffering from peritoneal and/or ovarian endometriosis with at least 15% of the endometriotic lesions observed at the study diagnostic laparoscopy being red inflammatory lesions and with a proven histological diagnosis.
- The Subject must consent to the scheduling of a second laparoscopy for surgical treatment at the study end.
- The Subject must have a history of pelvic pain for at least 3 months prior to the screening visit.
Exclusion Criteria:
- The Subject is over 40 years old and has a FSH serum level during Day 2-4 of her cycle ≥ 21.5 mIU/ml.
- The Subject has a positive pregnancy test at baseline or is breast-feeding or planning a pregnancy during the course of the study.
- The Subject is known for having a cause of chronic abdominal/pelvic pain other than endometriosis (e.g. inflammatory bowel disease, fibromyalgia, interstitial cystitis).
- The Subject has a history of surgical treatment for endometriosis prior to the study diagnostic laparoscopy.
- The Subject is requiring urgent surgical excision of endometriotic lesions at the time of first diagnostic laparoscopy.
- The Subject has a history (in the past 12 months) of or a current medical treatment for endometriosis other than NSAID (e.g. GnRH agonist or antagonist, danazol, continuous oral combined oestroprogestogens).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Part A2 - Active Treatment arm
PGL5001 for 8 weeks + one DMPA injection
|
PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection.
Second DMPA injection between 85 to 89 days after first injection
|
|
Placebo komparator: Part A2 - Placebo Treatment arm
PGL5001 matching placebo for 8 weeks + one DMPA injection
|
PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection.
Second DMPA injection between 85 to 89 days after first injection
|
|
Aktiv komparator: Part B - Active treatment arm
PGL5001 for 20 weeks + two DMPA injections
|
PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection.
Second DMPA injection between 85 to 89 days after first injection
|
|
Placebo komparator: Part B - Placebo Treatment arm
PGL5001 matching placebo for 20 weeks + two DMPA 150mg injections
|
PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection.
Second DMPA injection between 85 to 89 days after first injection
|
|
Eksperimentell: Part A1 - Active Treatment arm
PGL5001 for 8 weeks + one unique DMPA 150 mg injection
|
PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection.
Second DMPA injection between 85 to 89 days after first injection
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change from baseline to end of treatment in the number and percentage of red lesions (and/or inflammatory lesions), based on total number of red and black lesions.
Tidsramme: at week 8, week 20
|
at week 8, week 20
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Elke Bestel, MD, PregLem SA
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PGL11-021
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .